145 related articles for article (PubMed ID: 19927341)
1. Human epididymis protein 4 is a biomarker for transitional cell carcinoma in the urinary system.
Xi Z; LinLin M; Ye T
J Clin Lab Anal; 2009; 23(6):357-61. PubMed ID: 19927341
[TBL] [Abstract][Full Text] [Related]
2. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases.
Escudero JM; Auge JM; Filella X; Torne A; Pahisa J; Molina R
Clin Chem; 2011 Nov; 57(11):1534-44. PubMed ID: 21933899
[TBL] [Abstract][Full Text] [Related]
3. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
4. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
5. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
[TBL] [Abstract][Full Text] [Related]
6. [Level of CD4(+) CD25(high) CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its clinical significance].
Zhu X; Hu XZ; Ma LL; Tian Y
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(32):2269-72. PubMed ID: 20095340
[TBL] [Abstract][Full Text] [Related]
7. Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus.
Moore RG; Brown AK; Miller MC; Badgwell D; Lu Z; Allard WJ; Granai CO; Bast RC; Lu K
Gynecol Oncol; 2008 Aug; 110(2):196-201. PubMed ID: 18495222
[TBL] [Abstract][Full Text] [Related]
8. Utility of tumor marker HE4 to predict depth of myometrial invasion in endometrioid adenocarcinoma of the uterus.
Moore RG; Miller CM; Brown AK; Robison K; Steinhoff M; Lambert-Messerlian G
Int J Gynecol Cancer; 2011 Oct; 21(7):1185-90. PubMed ID: 21720250
[TBL] [Abstract][Full Text] [Related]
9. Serum Human Epididymis Secretory Protein 4 (HE4) is a Potential Prognostic Biomarker in Non-Small Cell Lung Cancer.
Mo D; He F
Clin Lab; 2018 Sep; 64(9):1421-1428. PubMed ID: 30274019
[TBL] [Abstract][Full Text] [Related]
10. HE4: a new potential early biomarker for the recurrence of ovarian cancer.
Anastasi E; Marchei GG; Viggiani V; Gennarini G; Frati L; Reale MG
Tumour Biol; 2010 Apr; 31(2):113-9. PubMed ID: 20358424
[TBL] [Abstract][Full Text] [Related]
11. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass.
Montagnana M; Lippi G; Ruzzenente O; Bresciani V; Danese E; Scevarolli S; Salvagno GL; Giudici S; Franchi M; Guidi GC
J Clin Lab Anal; 2009; 23(5):331-5. PubMed ID: 19774626
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
[TBL] [Abstract][Full Text] [Related]
13. Clinical Usefulness of Human Epididymis Protein 4 in Lung Cancer.
Choi SI; Jang MA; Jeon BR; Shin HB; Lee YK; Lee YW
Ann Lab Med; 2017 Nov; 37(6):526-530. PubMed ID: 28840992
[TBL] [Abstract][Full Text] [Related]
14. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD4(+)CD25(high)CD127(low/-) regulatory T cells in transitional cell carcinoma patients and its significance.
Zhu X; Ma LL; Ye T
J Clin Lab Anal; 2009; 23(4):197-201. PubMed ID: 19623656
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients.
Bignotti E; Ragnoli M; Zanotti L; Calza S; Falchetti M; Lonardi S; Bergamelli S; Bandiera E; Tassi RA; Romani C; Todeschini P; Odicino FE; Facchetti F; Pecorelli S; Ravaggi A
Br J Cancer; 2011 Apr; 104(9):1418-25. PubMed ID: 21468050
[TBL] [Abstract][Full Text] [Related]
17. HE4 as a biomarker for ovarian and endometrial cancer management.
Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
[TBL] [Abstract][Full Text] [Related]
18. Testing for urinary hyaluronate improves detection and grading of transitional cell carcinoma.
Passerotti CC; Srougi M; Bomfim AC; Martins JR; Leite KR; Dos Reis ST; Sampaio LO; Ortiz V; Dietrich CP; Nader HB
Urol Oncol; 2011; 29(6):710-5. PubMed ID: 19962919
[TBL] [Abstract][Full Text] [Related]
19. [Detection of circulating tumor cells from peripheral blood in patients with transitional cell carcinoma--pilot study. Comparison with the standard histopathological staging].
Nagy V; Rosocha J; Zidzik J; Bohus P
Klin Onkol; 2011; 24(4):287-92. PubMed ID: 21905620
[TBL] [Abstract][Full Text] [Related]
20. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting.
Jacob F; Meier M; Caduff R; Goldstein D; Pochechueva T; Hacker N; Fink D; Heinzelmann-Schwarz V
Gynecol Oncol; 2011 Jun; 121(3):487-91. PubMed ID: 21420727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
